ArticleScientific reports2025
inhibitory effect of hyperin on Staphylococcus aureus pathogenicity though interactions with sortase A and sortase B.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Sortase A (SrtA) and Sortase B (SrtB) promote S. aureus adhesion by anchoring a variety of virulence proteins to the surface of the cell wall, which in turn promotes the formation of bacterial biofilms and triggers cytotoxicity and inflammation. Therefore, inhibiting the function of SrtA and SrtB to block the anchoring of virulence proteins is a promising mechanism to alleviate the pathogenicity of S. aureus. In this study, we found that a natural compound named hyperin occupied the active pockets of SrtA and SrtB and inhibited their transpeptide capacity, which resulted in a reduction in bacterial biofilm formation and the adhesion of bacteria to lung epithelial cells. Hyperin did not have antimicrobial properties or cytotoxicity at the test concentrations but decreased the cytotoxicity and inflammation of cells induced by S. aureus USA300. In vivo, hyperin significantly alleviated the tissue damage and melanin formation of infected G. mellonella (G. mellonella) and improved the survival rate of the hyperin-treated group. In a mouse pneumonia model, hyperin improved the survival rate of mice infected with S. aureus USA300, and the bacterial burden and inflammatory factor levels decreased significantly. Taken together, our results confirm that hyperin is a promising reliable natural compound for combating diseases caused by S. aureus infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.